Dr. Ali is the primary investigator on a clinical trial to use a vaccine to extend remissions following successful myeloma treatment. The GVAX study is open for patients who are MRD positive but don't yet have a measurable m-protein. Dr. Ali explains how the vaccine works and why patients may want to use it to lengthen theri remission times.   Thanks to our episode sponsor, Bristol Myers Squibb.